Meeting
2020 ASCO Virtual Scientific Program
Preclinical evaluation of XPO1 inhibition in Wilms tumors.
Authors
Michael Vincent Ortiz
Memorial Sloan Kettering Cancer Center, New York, NY
Michael Vincent Ortiz , Armaan Siddiquee , Daoqi You , Prabhjot Singh Mundi , Lianna Marks , Kristina Guillan , Daniel Diolaiti , Mahalaxmi Aburi , Andrea Califano , Filemon S. Dela Cruz , Andrew Kung
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3580)
DOI
10.1200/JCO.2020.38.15_suppl.3580
Abstract #
3580
Poster Bd #
310
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).
First Author: Ulrik Niels Lassen
Poster
2015 Genitourinary Cancers Symposium
Effect of selinexor (KPT-330), a novel oral selective inhibitor of nuclear export (SINE), on tumor suppressors and cell cycle proteins in prostate cancer cells and regression of castration-resistant patient-derived xenograft tumor growth.
First Author: Sankar N. Maity
Poster
2020 ASCO Virtual Scientific Program
Product characteristics and pharmacological profile of KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in the phase II registrational ZUMA-2 trial.
First Author: Michael Wang
Poster
2019 Genitourinary Cancers Symposium
Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Jingsong Zhang